Surmodics, Inc. announced on September 22, 2025, early results from a subset analysis of 60 real-world limb ischemia patients in its PROWL registry study for the Pounce™ Thrombectomy Platform. The data, presented at the 36th Annual TCT Symposium, demonstrated a 96.8% procedural flow restoration rate.
The study highlighted that 81.7% of subjects did not require additional thromboemboli removal treatment after using the Pounce™ System. The cohort included a diverse patient population, with 60.0% presenting with acute, 16.7% with subacute, and 23.3% with chronic limb ischemia, showcasing the system's effectiveness across various clot chronicity.
These results suggest that the Pounce Thrombectomy System is effective as a standalone solution for removing acute-to-chronic clot in real-world clinical settings without the need for adjunctive thrombolytics or aspiration devices. Furthermore, 66.7% of patients avoided ICU admission and 81.7% were discharged home, indicating potential benefits in healthcare resource utilization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.